This study compared efficacy and safety of lipegfilgrastim with filgrastim in pediatric patients. Children and adolescents receiving chemotherapy (4 cycles) for Ewing sarcoma or rhabdomyosarcoma were ...

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...

Arialys Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study ...

TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant ...

Twenty-two patients participated in the NMS-Nab2 study between August 10, 2018, and January 31, 2020 (last patient last visit). There was no screening failure. Up-titration was started in all patients ...

Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved clinically meaningful reductions in blood Phe levels at month one of the open-label ...

Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma Patients with SCLC and progression on ...

Please provide your email address to receive an email when new articles are posted on . The blood test aims to predict lupus flares and drug targets rapidly by analyzing RNA gene expression.

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure 5.3% mean weight change observed with Revita (n=15); published third-par ...